Listed

Knowles Corp: Form 10-Q for the period ended Mar 31, 2025

Filed with the SEC on Apr 29, 2025 and accepted by EDGAR at Apr 29, 2025, 16:13 ET.

Share

Management's discussion and analysis

As filed, 37,979 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion and analysis should be read in conjunction with our Consolidated Financial Statements and related Notes included elsewhere in this Quarterly Report on Form 10-Q.

Overview

We are a leading manufacturer of specialty electronic components. We design parts that perform unique and critical functions for innovative technologies. Through extreme reliability, custom engineering, and scalable manufacturing, we enable businesses to succeed in the most demanding applications across medtech, defense, and industrial markets. Our high performance capacitors, radio frequency ("RF") and microwave filters, advanced medtech microphones, and balanced armature speakers, enhance the performance of our customers products to change, improve, and save lives. Our focus on the customer, combined with unique technology, proprietary manufacturing techniques, and global operational expertise, enables us to deliver innovative solutions across multiple applications. References to "Knowles," the "Company," "we," "our," or "us" refer to Knowles Corporation and its consolidated subsidiaries, unless the context otherwise requires.

We sell our products directly to original equipment manufacturers ("OEMs") and to their contract manufacturers and suppliers and through distributors worldwide.

Recent Developments

On April 2, 2025, the U.S. announced a new universal baseline tariff of 10%, plus an additional country-specific tariff for select trading partners, on all U.S. imports. These actions, and retaliatory tariffs imposed by foreign jurisdictions, has resulted in market volatility and uncertainty regarding the ultimate effect of the tariffs on global economic conditions. Based on a preliminary analysis, we do not anticipate that these factors will have a material impact on our operations; however, we continue to monitor changes in international trade relations and trade policy, including those related to tariffs, which could adversely impact our results. We are optimizing operations and leveraging existing programs and strategies to reduce the impact from tariffs. Additionally, we are taking measures to control costs and implementing pricing actions designed to mitigate the risk these policies may have on our revenues and operations.

On December 27, 2024, the Company consummated the sale and assignment of certain assets and liabilities of the Company’s Consumer MEMS Microphones ("CMM") business to Syntiant Corp. ("Syntiant") for approximately $150.0 million in total consideration, consisting of $70.0 million cash ($58.0 million in net cash received) as adjusted for agreed deductions for indebtedness, and working capital and $80.0 million in Syntiant Series D-2 preferred stock (with a fair value of $77.2 million), par value $0.0001. The Company provided $6.4 million in financing, which was utilized to fund Syntiant's requirement to have $40.0 million of cash on its balance sheet at closing. The Company will also share in certain separation costs pursuant to a credit, which Syntiant may apply to specified separation costs post-closing. For additional information, refer to Note 3. Discontinued Operations to our Consolidated Financial Statements under Part I, Item 1, "Financial Statements."

We have reclassified the results of operations and financial position of CMM to discontinued operations for all periods presented. Unless otherwise noted, our results of operations discussed below relate to continuing operations and will be impacted by the CMM divestiture.

This divestiture supports Knowles' continued transformation into an industrial technology company, consisting of its Precision Devices ("PD") and MedTech & Specialty Audio ("MSA") segments, primarily serving the defense, medtech, industrial, and electrification markets. We have incurred some amount of dis-synergies following the sale of the CMM business due to the reduced size of our company and, as a result, we have undertaken actions to help ensure that our cost structure is appropriate to support our remaining businesses.

As inventory levels in the industrial markets have recently begun to normalize, our Precision Devices segment has experienced increased distribution orders for the past two quarters. In addition, with bookings increasing we have seen backlog across our capacitor products increase for the past two quarters.

Non-GAAP Financial Measures

In addition to the GAAP financial measures included in this item, we have presented certain non-GAAP financial measures. We use non-GAAP measures as supplements to our GAAP results of operations in evaluating certain aspects of our business, and our executive management team and Board of Directors focus on non-GAAP items as key measures of our performance for business planning purposes. These measures assist us in comparing our performance between various reporting periods on a consistent basis, as these measures remove from operating results the impact of items that, in our opinion, do not reflect our core operating performance. We believe that our presentation of non-GAAP financial measures is useful because it provides investors and securities analysts with the same information that we use internally for purposes of assessing our core operating performance. The Company does not consider these non-GAAP financial measures to be a substitute for the information provided by GAAP financial results. For a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures, see the reconciliation included herein.

Results of Operations for the Three Months Ended March 31, 2025 compared with the Three Months Ended March 31, 2024

(in millions, except per share amounts)

Three Months Ended March 31, 2025 2024
Revenues $132.2 $133.3
Gross profit $53.3 $53.2
Non-GAAP gross profit $55.0 $57.9
Earnings from continuing operations before interest and income taxes $3.5 $5.4
Adjusted earnings from continuing operations before interest and income taxes $21.7 $23.3
Provision for income taxes $1.2 $2.0
Non-GAAP provision for income taxes $2.8 $1.9
Net loss from continuing operations $(0.4) $(1.0)
Non-GAAP net earnings $16.2 $17.0
Loss per share from continuing operations - diluted $— $(0.01)
Non-GAAP diluted earnings per share $0.18 $0.18

Revenues

Revenues for the first quarter of 2025 were $132.2 million, compared with $133.3 million for the first quarter of 2024, a decrease of $1.1 million or 0.8%. PD revenues decreased $1.8 million due to lower demand from the industrial market in our CD business and the defense market in our legacy PD business, partially offset by higher demand from the medtech market in our legacy PD business. MSA revenues increased $0.7 million, primarily due to higher shipping volumes of metal cans within the specialty audio market that we manufacture and sell to Syntiant as part of our supply agreement associated with the sale of CMM, partially offset by lower shipping volumes of hearing health products and unfavorable customer mix.

Cost of Goods Sold

Cost of goods sold ("COGS") for the first quarter of 2025 was $78.4 million, compared with $79.1 million for the first quarter of 2024, a decrease of $0.7 million or 0.9%. This decrease was primarily due to a reduction of CD related acquisition and production transfer costs, lower shipping volumes, and Company-wide product cost reductions, partially offset by unfavorable product mix, the absence of a one-time benefit in our MSA business recorded in the prior year, and inefficiencies in our CD business as we ramp up our specialty film product line.

Restructuring Charges

During the first quarter of 2025, we recorded restructuring charges of $0.5 million within Gross profit and $2.4 million within Operating expenses related to headcount reductions across the Company to rightsize operating expenses subsequent to the sale of the CMM business. For additional information, refer to Note 7. Restructuring and Related Activities to our Consolidated Financial Statements.

During the first quarter of 2024, we recorded restructuring charges of $1.8 million related to headcount reductions and $0.7 million for costs associated with transferring certain capacitors manufacturing to existing facilities to further optimize operations, all within our PD segment. For additional information, refer to Note 7. Restructuring and Related Activities to our Consolidated Financial Statements.

Gross Profit and Non-GAAP Gross Profit

Gross profit for the first quarter of 2025 was $53.3 million, compared with $53.2 million for the first quarter of 2024, an increase of $0.1 million or 0.2%. Gross profit margin (gross profit as a percentage of revenues) for the first quarter of 2025 was 40.3%, compared with 39.9% for the first quarter of 2024. The increases were primarily due to a reduction of CD related acquisition and production transfer costs, along with Company-wide product cost reductions, partially offset by unfavorable product mix, the absence of a one-time benefit in our MSA business recorded in the prior year, and production inefficiencies in our CD business as we ramp up our specialty film product line.

Non-GAAP gross profit for the first quarter of 2025 was $55.0 million, compared with $57.9 million for the first quarter of 2024, a decrease of $2.9 million or 5.0%. Non-GAAP gross profit margin (non-GAAP gross profit as a percentage of revenues) for the first quarter of 2025 was 41.6%, compared with 43.4% for the first quarter of 2024. The decreases were primarily due to unfavorable product mix, the absence of a one-time benefit in our MSA business recorded in the prior year, and production inefficiencies in our CD business as we ramp up our specialty film product line, partially offset by Company-wide product cost reductions.

Research and Development Expenses

Research and development expenses for the first quarter of 2025 were $9.7 million, compared with $9.4 million for the first quarter of 2024, an increase of $0.3 million or 3.2%. Research and development expenses as a percentage of revenues for the first quarter of 2025 and 2024 were 7.3% and 7.1%, respectively. The increase in expenses and as a percentage of revenues was primarily driven by increased development activities in both our PD and MSA segments as we continue to invest in our businesses.

Selling and Administrative Expenses

Selling and administrative expenses for the first quarter of 2025 were $37.2 million, compared with $37.3 million for the first quarter of 2024, a decrease of $0.1 million or 0.3%. Selling and administrative expenses as a percentage of revenues for the first quarter of 2025 and 2024 were 28.1% and 28.0%, respectively. The decrease in expenses was primarily driven by lower marketing costs, a change in our deferred compensation liability, the benefits of restructuring actions taken in the prior year, lower professional fees, and lower intangible amortization, partially offset by the acceleration of stock-based compensation expense for employees who are nearing or have reached retirement eligibility. The increase in expenses as a percentage of revenues was driven by lower revenues.

Interest Expense, net

Interest expense for the first quarter of 2025 was $2.7 million, compared with $4.4 million for the first quarter of 2024, a decrease of $1.7 million. The decrease is due to a lower outstanding revolving credit facility balance during the first quarter of 2025 and lower imputed interest expense on our Seller Note from the CD acquisition. For additional information on borrowings and interest expense, refer to Note 8. Borrowings to our Consolidated Financial Statements.

Other Expense (Income), net

Other expense for the first quarter of 2025 was $0.5 million, compared with income of $0.4 million for the first quarter of 2024, a change of $0.9 million. Expense in 2025 primarily represents unrealized losses in our investment balances. Income in the first quarter of 2024 primarily represents unrealized gains in our investment balances.

Provision for Income Taxes and Non-GAAP Provision for Income Taxes

The effective tax rate ("ETR") from continuing operations for the first quarter of 2025 and 2024 was 150.0% and 200.0%, respectively. The ETR from continuing operations for the first quarter of 2025 and 2024 includes discrete items totaling $0.5 million of tax benefit and $0.4 million of tax expense, respectively. The discrete items impacting the tax provision for 2025 and 2024 are primarily attributable to stock-based compensation. Absent the discrete items, the ETR from continuing operations for the first quarter of 2025 and 2024 was 212.5% and 160.0%, respectively. The Company accrues taxes in various countries where it generates income and applies a valuation allowance in other jurisdictions, which resulted in the provision for the first quarter of 2025 and 2024. The change in the ETR was mainly due to the mix of earnings and losses by taxing jurisdictions and net discrete items.

The non-GAAP ETR from continuing operations for the first quarter of 2025 and 2024 was 14.7% and 10.1%, respectively. The non-GAAP ETR from continuing operations includes no discrete impact for the first quarter of 2025 or 2024. The change in the non-GAAP ETR was primarily due to decreased utilization of foreign tax credits compared to the prior year.

Loss from Continuing Operations

Loss from continuing operations for the first quarter of 2025 was $0.4 million, compared with $1.0 million for the first quarter of 2024, an improvement of $0.6 million. As described above, the improvement is primarily due to lower interest and income tax expense, partially offset by higher operating expenses and other expense in the first quarter of 2025 compared to other income for the first quarter of 2024.

Earnings and Adjusted Earnings from Continuing Operations Before Interest and Income Taxes

Earnings from continuing operations before interest and income taxes ("EBIT") for the first quarter of 2025 was $3.5 million, compared with $5.4 million for the first quarter of 2024, a decrease of $1.9 million. EBIT margin (EBIT as a percentage of revenues) for the first quarter of 2025 was 2.6%, compared with 4.1% for the first quarter of 2024. The decrease in EBIT and EBIT margin was primarily due to higher operating expenses and other expense in the first quarter of 2025 compared to other income for the first quarter of 2024.

Adjusted earnings before interest and income taxes ("Adjusted EBIT") from continuing operations for the first quarter of 2025 was $21.7 million, compared with $23.3 million for the first quarter of 2024, a decrease of $1.6 million. Adjusted EBIT margin (Adjusted EBIT from continuing operations as a percentage of revenues) for the first quarter of 2025 was 16.4%, compared with 17.5% for the first quarter of 2024. The decrease in Adjusted EBIT and Adjusted EBIT margin was primarily due to lower non-GAAP gross profit margin, partially offset by lower non-GAAP operating expenses.

(Loss) Earnings from Discontinued Operations, net

Loss from discontinued operations for the first quarter of 2025 was $1.6 million, compared with earnings of $3.5 million for the first quarter of 2024, a decrease of $5.1 million. Loss from discontinued operations for the first quarter of 2025 was primarily driven by unfavorable working capital adjustments. Earnings from discontinued operations for the first quarter of 2024 was primarily driven by the gain on sale of asset, partially offset by income tax expense and additional expenses in connection with the sale of the CMM business. For additional information, refer to Note 3. Discontinued Operations to our Consolidated Financial Statements.

Diluted Loss per Share from Continuing Operations and Non-GAAP Diluted Earnings per Share from Continuing Operations

Diluted loss per share from continuing operations was nil for the first quarter of 2025, compared with a loss of $0.01 for the first quarter of 2024, an improvement of $0.01. As described above, the improvement is primarily due to lower interest and income tax expense, partially offset by higher operating expenses and other expense in the first quarter of 2025 compared to other income for the first quarter of 2024.

Non-GAAP diluted earnings per share from continuing operations was $0.18 for the first quarter of 2025 and the first quarter of 2024. As described above, there is no change primarily due to lower non-GAAP gross profit and higher non-GAAP income tax expense, offset by lower non-GAAP operating expenses and interest expense.

Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (1)

(in millions, except per share amounts)

Three Months Ended March 31, 2025 2024
Gross profit $53.3 $53.2
Stock-based compensation expense 0.5 0.4
Restructuring charges 0.5 1.0
Production transfer costs (2) 0.1 0.8
Acquisition-related costs (3) — 1.4
Transition services credit (4) (0.2) —
Other (5) 0.8 1.1
Non-GAAP gross profit $55.0 $57.9
Net loss from continuing operations $(0.4) $(1.0)
Interest expense, net 2.7 4.4
Provision for income taxes 1.2 2.0
Earnings from continuing operations before interest and income taxes 3.5 5.4
Stock-based compensation expense 10.2 5.1
Intangibles amortization expense 4.0 4.4
Restructuring charges 2.9 2.5
Production transfer costs (2) 0.2 0.8
Acquisition-related costs (3) 0.5 4.2
Transition services credit (4) (0.7) —
Other (5) 1.1 0.9
Adjusted earnings from continuing operations before interest and income taxes $21.7 $23.3
Provision for income taxes $1.2 $2.0
Income tax effects of non-GAAP reconciling adjustments (6) 1.6 (0.1)
Non-GAAP provision for income taxes $2.8 $1.9
Net loss from continuing operations $(0.4) $(1.0)
Non-GAAP reconciling adjustments (7) 18.2 17.9
Income tax effects of non-GAAP reconciling adjustments (6) 1.6 (0.1)
Non-GAAP net earnings $16.2 $17.0
Diluted loss per share from continuing operations $— $(0.01)
Earnings per share non-GAAP reconciling adjustment (8) 0.18 0.19
Non-GAAP diluted earnings per share $0.18 $0.18
Diluted average shares outstanding 87.8 89.6
Non-GAAP adjustment (9) 2.8 3.1
Non-GAAP diluted average shares outstanding (9) 90.6 92.7

26

(1) In addition to the GAAP financial measures included herein, Knowles has presented certain non-GAAP financial measures that exclude certain amounts that are included in the most directly comparable GAAP measures. Knowles believes that non-GAAP measures are useful as supplements to its GAAP results of operations to evaluate certain aspects of its operations and financial performance, and its management team primarily focuses on non-GAAP items in evaluating Knowles' performance for business planning purposes. Knowles also believes that these measures assist it with comparing its performance between various reporting periods on a consistent basis, as these measures remove from operating results the impact of items that, in Knowles' opinion, do not reflect its core operating performance. Knowles believes that its presentation of non-GAAP financial measures is useful because it provides investors and securities analysts with the same information that Knowles uses internally for purposes of assessing its core operating performance.

(2) Production transfer costs represent duplicate costs incurred to migrate manufacturing to facilities primarily within the United States. These amounts are included in the corresponding Gross profit and Earnings from continuing operations before interest and income taxes for each period presented.

(3) These expenses are related to the acquisition of CD by the PD segment. These expenses include ongoing costs to facilitate integration, the amortization of fair value adjustments to inventory, and costs incurred by the Company to carry out this transaction.

(4) Transition services represent amounts charged to Syntiant in connection with post-closing transition and separation costs

(5) Other expenses include non-recurring professional service fees related to the execution of various reorganization projects and foreign currency exchange rate impacts on restructuring balances.

(6) Income tax effects of non-GAAP reconciling adjustments are calculated using the applicable tax rates in the jurisdictions of the underlying adjustments.

(7) The non-GAAP reconciling adjustments to reconcile Earnings from continuing operations before interest and income taxes to Adjusted earnings from continuing operations before interest and income taxes include stock-based compensation expense, intangibles amortization expense, restructuring charges, production transfer costs, acquisition-related costs, and other expenses, partially offset by a credit to transition services.

(8) Non-GAAP diluted earnings per share includes reconciling adjustments on non-GAAP net earnings.

(9) The number of shares used in the diluted per share calculations on a non-GAAP basis excludes the impact of stock-based compensation expense expected to be incurred in future periods and not yet recognized in the financial statements, which would otherwise be assumed to be used to repurchase shares under the GAAP treasury stock method.

Segment Results of Operations for the Three Months Ended March 31, 2025 compared with the Three Months Ended March 31, 2024

The following is a summary of the results of operations of our two reportable segments: Precision Devices and Medtech & Specialty Audio.

See Note 14. Segment Information to the Consolidated Financial Statements for (i) a reconciliation of segment revenues to our consolidated revenues and (ii) a reconciliation of segment adjusted earnings before interest and income taxes to our consolidated earnings before income taxes and discontinued operations.

Precision Devices

(in millions)

Three Months Ended March 31, 2025 Percent of Revenues 2024 Percent of Revenues
Revenues $72.5 $74.3
Earnings (loss) from continuing operations before interest and income taxes $3.2 4.4% $(2.1) (2.8)%
Stock-based compensation expense 1.4 0.1
Intangibles amortization expense 4.0 4.4
Restructuring charges 1.4 2.5
Production transfer costs (1) 0.2 0.8
Acquisition-related costs (2) 0.5 3.6
Other — 0.5
Adjusted earnings from continuing operations before interest and income taxes $10.7 14.8% $9.8 13.2%
(1) Production transfer costs represent costs incurred to migrate manufacturing to existing facilities.
(2) These expenses are related to the acquisition of CD. These expenses include ongoing costs to facilitate integration.

Revenues

PD revenues were $72.5 million for the first quarter of 2025, compared with $74.3 million for the first quarter of 2024, a decrease of $1.8 million or 2.4%. Revenues decreased due to lower demand from the industrial market in our CD business and the defense market in our legacy PD business, partially offset by higher demand from the medtech market in our legacy PD business.

Earnings and Adjusted Earnings from Continuing Operations Before Interest and Income Taxes

PD EBIT was $3.2 million for the first quarter of 2025, compared with a loss of $2.1 million for the first quarter of 2024, an increase of $5.3 million. EBIT margin for the first quarter of 2025 was 4.4%, compared to (2.8)% for the first quarter of 2024. The increases were primarily due to lower operating expenses and higher gross profit. The decrease in operating expenses was primarily driven by lower acquisition-related costs, intangible amortization, and the benefits of restructuring actions, partially offset by higher stock-based compensation. The gross profit increase was primarily driven by a reduction of CD related acquisition and production transfer costs, product cost reductions, and lower restructuring charges, partially offset by unfavorable product mix and production inefficiencies in our CD business as we ramp up our specialty film product line.

PD Adjusted EBIT was $10.7 million for the first quarter of 2025, compared with $9.8 million for the first quarter of 2024, an increase of $0.9 million. Adjusted EBIT margin for the first quarter of 2025 was 14.8%, compared with 13.2% for the first quarter of 2024. The increases were primarily due to lower non-GAAP operating expenses, partially offset by lower non-GAAP gross profit. The decrease in non-GAAP operating expenses was primarily driven by the benefits of restructuring actions. The non-GAAP gross profit decrease was primarily driven by unfavorable product mix and production inefficiencies in our CD business as we ramp up our specialty film product line, partially offset by product cost reductions.

MedTech & Specialty Audio

(in millions)

Three Months Ended March 31, 2025 Percent of Revenues 2024 Percent of Revenues
Revenues $59.7 $59.0
Earnings from continuing operations before interest and income taxes $19.3 32.3% $22.8 38.6%
Stock-based compensation expense 1.7 1.0
Restructuring charges 0.3 —
Adjusted earnings from continuing operations before interest and income taxes $21.3 35.7% $23.8 40.3%

Revenues

MSA revenues were $59.7 million for the first quarter of 2025, compared with $59.0 million for the first quarter of 2024, an increase of $0.7 million or 1.2%. Revenues increased primarily due to higher shipping volumes of metal cans within the specialty audio market that we manufacture and sell to Syntiant as part of our supply agreement associated with the sale of CMM, partially offset by lower shipping volumes of hearing health products and unfavorable customer mix.

Earnings and Adjusted Earnings from Continuing Operations Before Interest and Income Taxes

MSA EBIT was $19.3 million for the first quarter of 2025, compared with $22.8 million for the first quarter of 2024, a decrease of $3.5 million or 15.4%. EBIT margin for the first quarter of 2025 was 32.3%, compared with 38.6% for the first quarter of 2024. The decreases were primarily due to lower gross profit and higher operating expenses. The gross profit decrease was primarily due to unfavorable product mix, the absence of a one-time benefit recorded in the prior year, and the impact of higher shipping volumes of our lower margin metal can products to Syntiant, partially offset by product cost reductions. The increase in operating expenses was primarily driven by higher stock-based compensation.

MSA Adjusted EBIT was $21.3 million for the first quarter of 2025, compared with $23.8 million for the first quarter of 2024, a decrease of $2.5 million. Adjusted EBIT margin for the first quarter of 2025 was 35.7%, compared to 40.3% for the first quarter of 2024. The decreases were primarily due to lower non-GAAP gross profit driven by unfavorable product mix, the absence of a one-time benefit recorded in the prior year, and the impact of higher shipping volumes of our lower margin metal can products to Syntiant, partially offset by product cost reductions.

Liquidity and Capital Resources

Historically, we have generated and expect to continue to generate positive cash flow from operations. Our ability to fund our operations and capital needs will depend on our ongoing ability to generate cash from operations and access to capital markets. We believe that our future cash flow from operations and access to capital markets will provide adequate resources to fund our working capital needs, capital expenditures, strategic investments, and share repurchases. We have secured a revolving line of credit in the United States from a syndicate of commercial banks to provide additional liquidity. Furthermore, if we were to require additional cash above and beyond our cash on the balance sheet, the free cash flow generated by the business, and availability under our revolving credit facility, we would most likely seek to raise long-term financing through the U.S. debt or bank markets.

Due to the global nature of our operations, a portion of our cash is generated and typically held outside the United States. Our cash and cash equivalents totaled $101.9 million and $130.1 million at March 31, 2025 and December 31, 2024, respectively. Of these amounts, cash held by our non-U.S. operations totaled $45.4 million and $92.4 million as of March 31, 2025 and December 31, 2024, respectively. To the extent we repatriate these funds to the U.S., we may be required to pay U.S. state income taxes and applicable foreign withholding taxes on those amounts during the period when such repatriation occurs. Management will continue to reassess our need to repatriate the earnings of our foreign subsidiaries.

On December 27, 2024, we completed the sale of the CMM segment to Syntiant for approximately $141.9 million in total consideration, consisting of $63.6 million in cash ($58.0 million net of cash sold), $1.1 million for estimated purchase price adjustments, and Series D-2 preferred stock of Syntiant with a fair value of $77.2 million. For additional information, refer to Note 3. Discontinued Operations to our Consolidated Financial Statements. We will also share in certain separation costs pursuant to a credit for up to $13.5 million, which the buyer may apply to specified separation costs post-closing. For additional information, refer to Note 1. Basis of Presentation.

On February 24, 2020, we announced that our Board of Directors had authorized a share repurchase program of up to $100.0 million of our common stock. On April 28, 2022, we announced that our Board of Directors had increased the authorization by up to $150.0 million in additional aggregate value. On February 13, 2025, the Company announced another authorization increase of up to $150.0 million in additional aggregate value. At March 31, 2025, we have $189.0 million remaining that may yet be repurchased under our share repurchase program. The timing and amount of any shares repurchased will be determined by us based on our evaluation of market conditions and other factors, and will be made in accordance with applicable securities laws in either the open market or in privately negotiated transactions. We are not obligated to purchase any shares under the program, and the program may be suspended or discontinued at any time. Any shares repurchased will be held as treasury stock. During the three months ended March 31, 2025, the Company repurchased 300,768 shares of common stock for a total of $5.0 million. The Company did not repurchase any shares of its common stock during the three months ended March 31, 2024.

Cash flows from operating, investing, and financing activities as reflected in our Consolidated Statements of Cash Flows and are presented on a consolidated basis, including discontinued operations. Cash flows are summarized in the following table:

(in millions)

Net cash flows provided by (used in): Three Months Ended March 31, 2025 2024
Operating activities $1.3 $17.3
Investing activities (3.5) 3.8
Financing activities (26.2) 13.6
Effect of exchange rate changes on cash and cash equivalents 0.2 0.1
Net (decrease) increase in cash and cash equivalents $(28.2) $34.8

30

Operating Activities

Cash provided by operating activities adjusts net earnings for certain non-cash items, including impairment charges, depreciation expense, amortization of intangible assets, stock-based compensation, changes in deferred income taxes, and the effects of changes in operating assets and liabilities. Excluding non-cash items, the decrease in cash provided by operating activities in 2025 is primarily due to $21.0 million of payments to settle supplier obligations and separation costs related to the CMM business and unfavorable changes in working capital driven by the timing of collections and payments, partially offset by customer prepayments of $19.8 million.

Investing Activities

The cash used in investing activities during 2025 was driven by capital expenditures, which is primarily driven by capacity expansion related to our specialty film product line and cost savings. The cash provided by investing activities during 2024 was primarily driven by proceeds from the sale of intellectual property, partially offset by capital expenditures to support product innovation and cost savings.

In 2025, we expect capital expenditures to be in the range of 4% to 6% of revenues.

Financing Activities

Cash used in financing activities during 2025 was primarily related to $15.0 million of payments on the revolving credit facility, $6.7 million of tax payments related to net share settlement of equity awards, and $5.0 million of repurchases of common stock, partially offset by proceeds of $0.6 million from the exercise of options. Cash provided by financing activities during 2024 was primarily related to $20.0 million of net borrowings on the revolving credit facility, partially offset by $5.8 million of tax payments related to net share settlement of equity awards.

Adjusted Free Cash Flow

In addition to measuring cash flow generation based on the operating, investing, and financing classifications included in the Consolidated Statement of Cash Flows (including discontinued operations), Knowles also measures adjusted free cash flow and adjusted free cash flow as a percentage of revenues. Adjusted free cash flow is defined as non-GAAP net cash attributable to continuing operations less non-GAAP capital expenditures attributable to continuing operations. Non-GAAP net cash attributable to continuing operations is defined as net cash provided by operating activities less amounts generated or utilized by discontinued operations. Non-GAAP capital expenditures attributable to continuing operations is defined as capital expenditures less amounts attributable to discontinued operations. Knowles believes these measures are helpful in measuring its cash generated from its continuing operations that is available to repay debt, fund acquisitions, and repurchase Knowles common stock. Adjusted free cash flow and adjusted free cash flow as a percentage of revenues are not presented in accordance with GAAP and may not be comparable to similarly titled measures used by other companies in our industry. As such, adjusted free cash flow and adjusted free cash flow as a percentage of revenues should not be considered in isolation from, or as an alternative to, any other liquidity measures determined in accordance with GAAP.

The following table reconciles our adjusted free cash flow to cash flow provided by operating activities:

(in millions)

Three Months Ended March 31, 2025 2024
Net cash provided by operating activities $1.3 $17.3
Less: amounts utilized (generated) by discontinued operations 21.0 (1.1)
Non-GAAP net cash attributable to continuing operations 22.3 16.2
Capital expenditures (4.0) (3.4)
Less: amounts attributable to discontinued operations — 0.5
Non-GAAP capital expenditures attributable to continuing operations (4.0) (2.9)
Non-GAAP net cash attributable to continuing operations 22.3 16.2
Non-GAAP capital expenditures attributable to continuing operations (4.0) (2.9)
Adjusted free cash flow $18.3 $13.3
Adjusted free cash flow as a % of revenues 13.8% 10.0%

In 2025 we generated adjusted free cash flow of $18.3 million compared to adjusted free cash flow of $13.3 million in 2024. The increase in adjusted free cash flow in 2025 was primarily due to customer prepayments of $19.8 million, lower incentive compensation payments and reduced restructuring payments, partially offset by unfavorable changes in working capital and accruals driven by the timing of collections and payments.

Contingent Obligations

We are involved in various legal proceedings, claims, and investigations arising in the ordinary course of business. Legal contingencies are discussed in Note 13. Commitments and Contingent Liabilities to our Consolidated Financial Statements.

Critical Accounting Estimates

This discussion and analysis of results of operations and financial condition is based on our Consolidated Financial Statements, which have been prepared in conformity with U.S. GAAP. The preparation of these financial statements requires the use of estimates and assumptions related to the reporting of assets, liabilities, revenues, expenses, and related disclosures. In preparing these financial statements, we have made our best estimates and judgments of certain amounts included in the financial statements. Estimates are revised periodically. Actual results could differ from these estimates.

The information concerning our critical accounting estimates can be found under Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on February 13, 2025. There are no material changes in our previously reported critical accounting estimates.

Recent Accounting Standards

The issuance of recent accounting standards, as included in Note 2. Recent Accounting Standards to our Consolidated Financial Statements, is not expected to have a significant impact on our revenue, earnings, or liquidity.

Market risk

As filed, 434 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

During the three months ended March 31, 2025, there were no material changes to the information on market risk exposure disclosed in our Annual Report on Form 10-K for the year ended December 31, 2024. For a discussion of our exposure to market risk as of December 31, 2024, refer to Item 7A, Quantitative and Qualitative Disclosures about Market Risk, contained in our Annual Report on Form 10-K for the year ended December 31, 2024.

Controls and procedures

As filed, 2,963 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Our management has evaluated, under the supervision and with the participation of our chief executive officer ("CEO") and chief financial officer ("CFO"), the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this report. Based on that evaluation, our CEO and CFO have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that information required to be disclosed in our Exchange Act reports is (1) recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (2) accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There has been no change in our internal control over financial reporting that occurred during the first quarter of 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including the CEO and CFO, do not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, will be detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by intentionally falsified documentation, by collusion of two or more individuals within Knowles or third parties, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

Risk factors

As filed, 183 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes from the risk factors previously disclosed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2025-01-01 to 2025-03-31$132.2mus-gaap:Revenues
Cost of revenue3 months2025-01-01 to 2025-03-31$78.4mus-gaap:CostOfRevenue
Gross profit3 months2025-01-01 to 2025-03-31$53.3mus-gaap:GrossProfit
Research and development3 months2025-01-01 to 2025-03-31$9.7mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2025-01-01 to 2025-03-31$37.2mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2025-01-01 to 2025-03-31$4.0mus-gaap:OperatingIncomeLoss
Income tax3 months2025-01-01 to 2025-03-31$1.2mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2025-01-01 to 2025-03-31−$2.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2025-01-01 to 2025-03-31−$0.02us-gaap:EarningsPerShareDiluted
Basic EPS3 months2025-01-01 to 2025-03-31−$0.02us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2025-01-01 to 2025-03-3187,800,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2025-01-01 to 2025-03-31$1.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2025-01-01 to 2025-03-31$4.0mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases3 months2025-01-01 to 2025-03-31$5.0mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2025-03-31$101.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-03-31$337.9mus-gaap:AssetsCurrent
Total assetsAt period end2025-03-31$1.10bnus-gaap:Assets
Current liabilitiesAt period end2025-03-31$167.6mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2025-03-31$119.0mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2025-03-31$69.8mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2025-03-31$755.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001587523-25-000037. Last ingested by Listed: Nov 11, 2026, 02:23 ET. Listed shows no prices and gives no investment advice.